Lipid nanoparticle systems (LNPs) as a delivery mechanism for novel drug modalities are proving effective, but there are bioanalytical challenges associated with encapsulation, says an expert.
Evonik says it is working with Stanford University, California on a technology to deliver mRNA to tissues and organs that goes beyond the capabilities of lipid nanoparticles (LNPs).
Previously Rexgenero Ltd, a UK-based company developing cell therapies to treat serious diseases such as cancer and CLTI, the launch of Ixaka Ltd follows the integration of its nanoparticle gene therapy business in France and a shareholder restructuring....
N4 Pharma creates DNA and RNA transfection technology using silica nanoparticles with an irregular surface, which traps and protects nucleic acid during its journey to cells.